Alkermes Update (11-02-12)

Alkermes reported financial results for its second quarter of fiscal 2013, which ended Sept. 30, 2012, and the company provided improved financial expectations for its fiscal year 2013. Total revenues for the second quarter of fiscal 2013 increased more than 72% to $124.0 million, compared to the same period in fiscal 2012, which was attributable[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Novavax Update (11-02-12)

NovaVax announced that it has raised a total of $27 million through the sale of 12,285,321 shares of its common stock to RA Capital Management, Camber Capital Management and Ayer Capital Management at a price of $2.18 per share. The shares were offered under an effective shelf registration statement previously filed with the Securities and[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Dick Davis Investment Digest (10-23-12)

October 23, 2012 How to Find the Best Biotech Stocks Written By Chloe Lutts Have you ever wondered how to find great biotech stocks in a sea of hopeful but high-risk medical small caps? Well, for my latest Dick Davis Digest contributor interview, I interviewed John McCamant, the editor of a top-performing investment newsletter that’s all about[…]

Posted on by

MarketWatch (9-6-12)

September 6, 2012 Dizzying gains, stupefying losses in medical tech Commentary: A veteran newsletter repeats its ‘Matterhorn’ pattern Written By Peter Brimelow NEW YORK (MarketWatch) — Medical Technology Stock Letter continues to Matterhorn. What does that say about the market? The long established letter — editor John McCamant is the son of the founding editor,[…]

Posted on by

Anthera Update (11-02-12)

Anthera’s stock is up since the last Issue as they have had two encouraging announcements. The most important was this week when they announced that an abstract from the Phase 2b PEARL-SC clinical study examining the treatment effect of blisibimod in systemic lupus patients has been accepted as a Late-Breaking poster presentation at the 2012 Annual[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Market Playground (10-25-12)

October 25, 2012 John McCamant on Investing in Blood Cancer Written By George S. Max Hematological cancers present special opportunities for investors.  In this exclusive interview with The Life Sciences Report, John McCamant, editor of the Medical Technology Stock Letter, comments on several companies in the hematology/oncology space, describing the challenges and successes that influence investment in the sector.[…]

Posted on by

Celgene Update (10-19-12)

Celgene’s stock is down since the last Issue as it also corrected this Friday. This week, additional information became available on the FDA’s website regarding the cancellation of the November 8th ODAC meeting originally scheduled to discuss pomalidomide. The website now specifically says that ”the issues for which the FDA was seeking the scientific input of the[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Aastrom Update (11-02-12)

Aastrom has announced that cell therapy regulatory and development expert Joyce L. Frey-Vasconcells, Ph.D. has been appointed to the company’s Scientific Advisory Board (SAB). Dr. Frey-Vasconcells is considered one of the foremost regulatory experts on cell therapies, tissues and gene therapies.  Dr. Frey-Vasconcells is founder and president of Frey-Vasconcells Consulting LLC and previously served as a[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Life Sciences Report (10-25-12)

Out of the Red and into the Black: John McCamant on Investment in Blood Cancer Companies TICKERS: AMGN, ASTX, CELG, CYCC, DNDN, PCYC, RHHBY October 25, 2012 Source: George S. Mack of The Life Sciences Report Hematological cancers present special opportunities for investors. In this exclusive interview with The Life Sciences Report, John McCamant, editor of the Medical Technology[…]

Posted on by

Life Sciences Report Instablog (10-4-12)

October 4, 2012 Pick Biotech Winners Like A Pro: John McCamant Written By George S. Mack John McCamant, editor of the Medical Technology Stock Letter, doesn’t care if a scientist or a businessperson is at the helm of a biotech company, as long as management has skill and broad experience. Investors need to look for companies that[…]

Posted on by

 ISSUE No. 801 | March 21, 2015 IN THIS ISSUE: March Madness; Guest Analyst Recommends ACAD Since Last Issue: BTK: 4.7%; NBI: 4.9%; Model Portfolio: 2.6%; Trader’s Portfolio: 4.0%   Clinical Trial Watch Relevant New Studies or Changes Posted on ClinicalTrials.gov for our MTSL Portfolio and/or Related Companies since last Issue: AMGN – Trial Assessing[…]

Posted on by